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Background. Three cortical atrophy patterns were previously identified in non-demented 
Parkinson’s disease patients using a data-driven approach based on cortical thickness 
data: i) parieto-temporal pattern of atrophy with worse cognitive performance (pattern 
1), ii) occipital and frontal cortical atrophy with younger disease onset (pattern 2), and iii) 
non-detectable cortical atrophy (pattern 3). We aimed to investigate the evolution of these 
three patterns over time. Methods. Magnetic resonance imaging and neuropsychological 
assessment were obtained at baseline and follow-up (3.8±0.4 year apart) in a group of 45 
Parkinson’s disease patients and 22 healthy controls. FreeSurfer was used for cortical 
thickness analysis and global atrophy measures. Results. Temporo-parietal cortical 
thinning occurred in pattern 2, 3 and controls groups, and patients showed decline in 
processing speed (as measured by the Stroop Word-Color test, the Symbol Digits 
Modalities test and the Trail Making Test Part B) and in semantic fluency (animals). 
Pattern 3 patients showed more progressive cortical thinning in the left prefrontal cortex 
than controls and more right occipital thinning than pattern 2 patients over time. Pattern 
1 patients had greater compromise in activities of the daily living and suffered higher 
attrition rate. Conclusion. The Parkinson’s disease phenotypes identified using cluster 
analysis of cortical thickness data showed different progression over time. The presence of 
prefrontal thinning and younger disease onset at baseline was associated to less cortical 







Impaired cognitive functions in Parkinson’s disease (PD) are present even in untreated 
patients and around 20% fulfill criteria for mild cognitive impairment (MCI) [1]. The 
cumulative prevalence of dementia during eight years’ evolution is near 80% [2]. A meta-
analysis performed in 2007 including 25 heterogeneous longitudinal studies reported that 
significant cognitive decline was obtained for global cognitive ability, visuoconstructive 
skills and memory functions [3]. Posteriorly, well-controlled prospective works coincided 
that the greatest decline was seen in psychomotor speed followed by memory functions, 
but disagreed regarding the progression of attention deficits [4–6]. It has been suggested 
that the neuropsychological functions sensitive to cognitive decline and progression to 
dementia are those supported by regions of the posterior cortex [7,8].  
Longitudinal magnetic resonance imaging (MRI) studies have contributed to establish the 
brain substrates for cognitive decline in PD. Voxel-wise and vertex-wise analyses 
demonstrated that demented and non-demented PD patients had gray matter (GM) 
reductions over relatively short periods of time [9–11] and these reductions were more 
remarkable in patients with visual hallucinations [12]. In addition to hallucinations, the 
presence of MCI is also a predictor of higher rates of cortical thinning [13]. The differences 
between studies in cortical and subcortical regions that suffer atrophy during the course 
of the disease could be due to the heterogeneity of the disease. A clinical subtype named 
diffuse/malignant presenting non-motor features such as MCI, orthostatic hypotension 
and rapid eye movement sleep behavior disorder, showed a more rapid progression of 
cognitive decline [14]. Thus, different phenotypes could lead to different patterns of 
cortical degeneration.  
In a previous study using cluster analysis of cortical thickness data in PD patients, we 
identified three PD subtypes: (i) parieto-temporal pattern of atrophy associated with 





PD onset, and (iii) patients without manifest cortical atrophy [15]. In the current study, we 
aimed to investigate longitudinally the evolution of these three different cortical atrophy 
patterns over a 4-year period.  
 
2. Methods 
2.1 Participants  
Forty-five PD patients from the Parkinson’s Disease and Movement Disorders Unit, 
Hospital Clinic (Barcelona, Spain) and 22 HC from the Aging Institute in Barcelona were 
assessed twice at 3.8±0.4 years apart (range: 3.1-5.3).  
At time 1, 88 PD patients and 31 HC were recruited between October 2010 and March 
2012 and classified into three subtypes as previously described [15]. In the present study, 
only subjects who underwent comprehensive neuropsychological and MRI evaluation at 
both times were included.  Briefly, 7 out of the 30 patients in pattern 1, 16/29 in pattern 2, 
22/29 in pattern 3 and 22/31 in the controls group returned to follow-up at time 2 (see 
the flowchart in Supplementary Figure 1 for dropout reasons). 
Inclusion criteria for patients at both time 1 and 2 were: (i) fulfilling the UK PD Society 
Brain Bank diagnostic criteria for PD; (ii) no surgical treatment with deep-brain 
stimulation. Exclusion criteria for PD patients and HC were: (i) dementia according to the 
Movement Disorders Society (MDS) criteria (only applicable for time 1)  and clinic 
assessment performed by clinical neurologist (MJM, FV, YC), (ii) Hoehn and Yahr (H&Y) 
scale score > 3 (only applicable for time 1), (iii) young-onset PD, (iv) age below 50 years, 
(v) presence of severe psychiatric or neurological comorbidity, (vi) low global intellectual 
quotient estimated by the Vocabulary subtest of the Wechsler Adult Intelligence Scale, 
(scalar score ≤ 7), (vii) Mini Mental State Examination (MMSE) score below 25 (only 
applicable for time 1), (viii) claustrophobia, (ix) pathological MRI findings other than mild 





Motor symptoms were assessed with the Unified Parkinson’s Disease Rating Scale, motor 
section (UPDRS-III). All PD patients were taking antiparkinsonian drugs, consisting of 
different combinations of L-DOPA, cathecol-O-methyltransferase inhibitors, monoamine 
oxidase inhibitors, dopamine agonists and amantadine. In order to standardize doses, the 
L-DOPA equivalent daily dose (LEDD) [16] was calculated. 
Written informed consent was obtained from all study participants after full explanation 
of the procedures. The study was approved by the institutional Ethics Committee from the 
University of Barcelona (IRB00003099). 
2.2 Neuropsychological and clinical assessment 
In line with MDS PD-MCI task force recommendations [17], we assessed five cognitive 
domains: visuospatial and visuoperceptual functions, executive functions, verbal memory, 
attention and working memory and language (see Uribe et al., [15] for detailed protocol). 
As in the baseline study [15], adjusted z-scores were calculated and the presence of MCI 
was established if the z-score for a given test was at least 1.5 lower than the expected 
score in at least two tests. Furthermore, the presence of dementia was determined if 
MMSE score was below 26, or if there was cognitive impairment in more than one domain 
and impaired instrumental activities of daily living (IADL). 
Neuropsychiatric symptoms were evaluated with the Beck Depression Inventory-II, 
Starkstein’s Apathy Scale and Cumming’s Neuropsychiatric Inventory. Functioning in IADL 
were assessed with the Lawton and Brody scale and the Schwab and England scale. 
Additionally, the Gottfries-Brane-Steen scale (GBS) was administered to caregivers/family 
members of PD patients that could not return at time 2 (non-completers) via telephone 
interview. This scale was administered with the aim to obtain qualitative information from 
patients lost to follow-up, specially concerning pattern 1 patients. 
2.3 Preprocessing and analysis of longitudinal imaging data 
MRI data were acquired with a 3T scanner (MAGNETOM Trio, Siemens, Germany) at both 





acquired in the sagittal plane (TR=2300ms, TE=2.98ms, TI=900ms, 240 slices, 
FOV=256mm; 1mm isotropic voxel) and an axial FLAIR sequence (TR=9000ms, TE=96ms). 
Cross sectional preprocessing of both times was estimated using the automated 
FreeSurfer stream (version 5.1; available at: http://surfer.nmr.harvard.edu). Detailed 
description of FreeSurfer procedures is reported in the baseline study [15] and 
information about the longitudinal cortical thickness preprocessing and the computed 
symmetrized percent of change (SPC) of cortical thickness are described elsewhere, 
https://surfer.nmr.mgh.harvard.edu/fswiki/LongitudinalTwoStageModel [18]. Cortical 
thickness and SPC maps were smoothed using a circularly symmetric Gaussian kernel 
across the surface with a full width at half maximum of 15 mm. 
2.4 Statistical analysis 
2.4.1. Demographic variables 
Group differences in demographic variables (Table 1) were analyzed with Kruskal-Wallis 
test followed by Mann-Whitney’s pairwise comparisons and Bonferroni correction for 
quantitative measures. Chi squared test were used where appropriate for categorical 
measures. These analyses were conducted using IBM SPSS Statistics 22.0 (2013; Armonk, 
NY: IBM Corp). 
2.4.2 Repeated measures analyses of clinical and neuropsychological variables 
Group by time interaction effects in clinical disease-related variables and 
neuropsychological performance between pattern 2 and 3 patients and HC were assessed 
through a repeated-measures general linear model and permutation testing with 10,000 
iterations. To control type-I errors, a Bonferroni correction was applied. The repeated 
measures general linear model was performed with Matlab R2017a (The MathWorks, Inc., 
Natick, Massachusetts). 
2.4.3 Cortical thickness analyses 






Intergroup comparisons at baseline were performed between patients in pattern 2, 
pattern 3 and healthy controls. Vertex-wise cortical thickness information was included as 
dependent variable and age and years of education were regressed out as variables of no 
interest (see Table 1).  
Longitudinally, two statistical models were performed: one sample t-test was performed 
to test time effect in groups (if the SPC was different from zero); and to test time by group 
interaction effects, SPC was included as a dependent factor and group as an independent 
factor. In the second model, age (controls vs pattern 2) and years of education (controls vs 
pattern 2; pattern 2 vs pattern 3) were considered as nuisance covariates (see Table 1). 
Both longitudinal designs were performed as a whole-brain vertex-wise approach. 
All results were corrected for multiple comparisons using pre-cached cluster-wise Monte 
Carlo simulation with 10,000 iterations. Reported cortical regions reached a two-tailed 
corrected significance level of p < 0.05.  
2.4.4 Repeated measures analyses of global atrophy measures 
Global atrophy measures including total GM volume, subcortical and cortical GM volume, 
mean lateral ventricular volume and estimated intracranial volume were obtained 
automatically via whole brain segmentation with the FreeSurfer suite. Global average 
thickness for both hemispheres was calculated as:  
((lh.thickness*lh.surface area)+(rh.thickness*rh.surface area))/(lh.surface area+rh.surface 
area). 
Matlab R2017a (The MathWorks, Inc., Natick, Massachusetts) was used to perform group 
by time interaction effects assessed by permutation test statistics with 10,000 iterations 
using a general linear model of repeated measures. Bonferroni was then used to control 
for multiple comparison. The estimated intracranial volume was considered as a nuisance 
covariate in the volumetric analyses.  





Due to the high attrition rate, and to further understand the characteristics of the present 
longitudinal sample in comparison with the initial one, we compared patients within each 
subgroup that returned to follow-up (completers) with those that were lost to follow-up 
(non-completers). Group differences in demographic and clinical variables between 
completers and non- completers were analyzed with Mann-Whitney’s U test for 
quantitative measures and Chi squared test for categorical measures at time 1. In addition, 
GBS scores at time 2 of the PD non-completers were assessed with Kruskal-Wallis test 
followed by Mann-Whitney’s pairwise comparisons and Bonferroni correction. In GBS 
analyses, we did not have available healthy controls non-completers information and 
group comparisons were performed between PD patients’ subgroups. These analyses 
were conducted using IBM SPSS Statistics 22.0 (2013; Armonk, NY: IBM Corp). 
3. Results 
There were no significant differences in the assessment interval between groups 
(H=6.516; P=.089).  
3.1 Demographical characteristics 
Pattern 2 patients were younger than both HC and pattern 1, younger at disease onset 
than pattern 1, and had more years of education than patients in pattern 1 and 3 and HC 
(Table 1).  
Regarding functioning in IADLS, patients in pattern 1 had significantly more impairment 
than HC and pattern 3 patients as measured by the Lawton and Brody scale at time 2. 
There were also significant differences between HC and pattern 1, pattern 2 and pattern 3 
as measured by the Schwab and England scale (Table 1).  
3.2 Repeated measures of clinical and neuropsychological variables 
Clinical variables. Pattern 2 patients and controls had significant time effects in the MMSE 
scores as measure of global cognition although they were not clinically significant. 
Regarding L-DOPA intake, a significant interaction was found between the decreased 





Regarding psychiatric symptoms over time, patients in pattern 2 had more severe global 
neuropsychiatric symptoms than HC (Table 2).  
Due to the high attrition rate in Pattern 1 patients, this group (n = 7) was not included in 
the statistical general linear models to investigate cortical thinning progression, clinical 
evolution and neuropsychological decline.  
Neuropsychological variables. Both pattern 2 and 3 patients as well as the controls group 
had worsened their performance over time in the Trail Making Test (TMT) Part A minus B. 
Specific effect times were found in pattern 2 and 3 patients’ groups. Pattern 2 and pattern 
3 patients also had decreased performance in semantic fluency, Stroop Word-Color test, 
Symbol Digits Modalities test (SDMT) and in the TMT Part B over time. Additionally, 
pattern 2 patients also showed decline in the Stroop Color test. Pattern 3 patients 
performed worse over time also in the TMT Part A. Patients in pattern 2 declined 
significantly more than HC in Stroop Color test and SDMT. Pattern 3 patients differed from 
HC in TMTA, TMTB and SDMT (Figure 1A). In Supplementary Table 1 means and SD of the 
neuropsychological performance can be found for all groups. 
At time 2, 2 (28.6%) patients in pattern 1 converted to dementia and 3 (28.6%) patients 
had MCI. From the 3 MCI patients, two were converters and the other already had MCI at 
time 1. In pattern 2 subtype, there were 7 MCI (43.8%), 4 of whom were converters, 
whereas in pattern 3 there were 11 MCI (50.0%), 6 of whom were converters. In the HC 
group, 1 (4.5%) control also converted to MCI (Table 1 and Supplementary Table 2). 
3.3 Cortical thickness changes  
At time 1, there were no significant regional cortical thickness differences between pattern 
2, pattern 3 and healthy controls subjects.  
Regarding changes over time, patients in pattern 2 had reductions in left parahippocampal 
gyrus, left precuneus and right inferior parietal and temporal gyri, fusiform and lateral 
occipital gyri. Significant cortical thinning in pattern 3 patients was found bilaterally in 





extending to frontal regions such as the precentral and postcentral gyri and the left pars 
opercularis. HC group also showed a significant effect of time, specifically cortical thinning 
was found in posterior regions, such as right parahippocampal, bilateral fusiform, 
posterior cingulate, lateral occipital, lingual gyri and both inferior and superior parietal 
areas extending to the right precentral gyrus. A small cluster of cortical thickening was 
found in the right prefrontal cortex (Figure 1B). 
Pattern 3 had more cortical thinning in the left pars opercularis and precentral gyri 
compared with HC over time (see Figure 2). There were no significant intergroup 
differences in cortical thickness decline between HC and pattern 2.  
Differential changes in cortical thinning were also found between pattern 2 and 3 (Figure 
2). Pattern 3 patients had more significant decrements in the right lateral occipital, lingual 
and pericalcarine gyri compared with pattern 2 patients.  
Montreal Neurological Institute coordinates, cluster sizes and significance from 
longitudinal analyses are summarized in Supplementary Table 3.  
3.4 Global atrophy changes 
Both pattern 2 and pattern 3 patients as well as the controls group suffered significant 
volume decrements in the total GM volumes. Specifically, pattern 2 patients had significant 
time effects in subcortical GM volumes whereas pattern 3 patients and healthy controls 
had significant decrements in the cortical GM volumes over time. From the group x time 
contrasts, total GM and cortical GM volumes were significantly more decreased in pattern 
3 patients than in pattern 2 patients. In addition, pattern 3 patients had more increased 
lateral ventricle volume over time than pattern 2 patients (Supplementary Table 4). 
3.5 Additional results 
As supplementary material, we provide the demographic and clinical features between PD 
patients’ completers and non-completers within each pattern and within the controls 





In pattern 1 patients, the proportion of females (chi=4.658; P=.031) and the H&Y stages 
scores (chi=10.784; P=.029) were higher in non-completers than in completers. In the 
pattern 2 subtype, non-completers had less years of education (U=40.500; P=.004), had 
lower global cognition scores (U=58.500; P=.045) and were more depressed (U=108.000; 
P=.026) than completers. Non-completers in the pattern 3 subtype had higher LEDD 
(U=122.000; P=.021), see Supplementary Table 5.   
Regarding GBS information, only PD non-completers were contacted for telephonic 
interview. PD non-completers in pattern 1 had more severe intellectual impairment, more 
impairment in IADL, more symptoms associated to dementia and more GBS global scores 
than non-completers in both pattern 2 (GBS-I: P=.004; GBS-ADL: P=.007; GBS-S: P=.017; 
GBS total score: P=.005) and pattern 3 (GBS-I: P=.007; GBS-ADL: P=.004; GBS-S: P=.016; 
GBS total score: P=.004). Pattern 1 non-completers also had more emotional impairment 
than pattern 3 non-completers (P=.021). See Supplementary Table 6. 
4. Discussion 
Remarkably, the results from MRI structural analyses showed that cortical thickness has a 
high sensitivity to time effects. In a period of four years, both patients and controls had 
cortical thinning mainly in parieto-temporal regions, as well as global gray matter atrophy.  
However, PD patients differed in clinical, cognitive and structural degeneration over time 
according to their initial regional cortical thinning pattern. 
Patients from pattern 1 characterized by an extensive parieto-temporal atrophy [15] 
showed a higher attrition rate and for that reason they were not included in the 
quantitative MRI analyses. This group showed higher severity of motor symptoms 
measured by the H&Y scale at baseline, more IADL, and more cognitive impairment 
assessed by telephone interview at follow-up.  Previous longitudinal studies also reported 
that patients who were lost to follow-up were older, had higher age at disease onset, more 





[5]. Considering the initial sample, we estimated that 15% of PD patients converted to 
dementia during the follow-up period. This percentage was similar to other population-
based studies [5,8,19,20].  
The time effect in pattern 2 patients, initially identified as frontal and occipital atrophy 
pattern [15], showed localized cortical thinning over time mainly in temporal, parietal and 
occipital lobes. These patients were initially younger, with higher education and younger 
age at onset, probably as indicators of better prognosis. Patients from pattern 2 who 
dropped out of the study had less years of education, more global cognitive impairment 
and had more depressive symptoms. Thus, patients from pattern 2 who completed the 
follow-up assessment probably represent a PD group with better progression of these 
disease aspects. Indeed, the lack of cortical thickness differences between pattern 2 
patients that returned to follow-up in comparison with healthy controls and pattern 3 
patients at time 1 supports the idea that completers had better disease progression than 
non-completers. 
On the other hand, pattern 3 and healthy controls that initially were identified as the less 
atrophic groups, showed an extensive cortical thinning effect in bilateral parietal and 
temporal regions. This time effect in pattern 3 was similar to cortical atrophy previously 
detected in pattern 1 at baseline [15] and it is similar to the cortical degeneration 
observed in the controls group. Additionally, a small cluster of cortical thickening was 
found in the right prefrontal cortex within the controls group. This finding could be due to 
methodological issues. 
Inter-group comparisons of symmetrized percent of cortical thickness change showed that 
pattern 3 patients had statistically significant greater cortical atrophy compared with 
healthy controls and pattern 2. Although this group was initially non-atrophic, after a four-
year period, they presented significant cortical thinning. These patients differed from 
normal aging in the left frontal lobe and showed higher symmetrized percent of change in 





region. Occipital thinning compared to controls has been observed in cross sectional [21] 
and longitudinal studies in demented PD patients [9], in PD-MCI [22] and in PD with visual 
hallucinations [23,24].  However, these studies also reported more widespread atrophy 
including other lobes.  
 Global atrophy measures also revealed higher volume decrements in pattern 3 patients 
than in pattern 2, as well as increased ventricular enlargement. Previous literature has 
reported an association between global atrophy measures [25,26] with cognitive 
impairment. However, the proportion of MCI was not significantly different between 
pattern 2 and 3.   
Regarding the neuropsychological assessment, our results identified that semantic fluency, 
TMT, SDMT and Stroop tests were sensitive to time effect. Decline in TMT, SDMT and 
Stroop tests as measured of processing speed agrees with previous findings in longitudinal 
studies showing processing speed impairment in PD over time assessed by Digit Symbol 
Test and TMTA [4,5]. Contrarily to the expected results accounted by aging effects, we did 
not find statistical memory decline. This could be due to a test-retest effect. In favor of this 
interpretation we can see that, although non-significant, the healthy control group showed 
a slight increase in their performance. Other longitudinal studies reported memory loss 
but the follow up was longer [3,5].  After four years, patients from patterns 2 and 3 
showed reduced semantic fluency performance. At baseline, semantic fluency test 
differentiated the parieto-temporal pattern from other PD subtypes [15]. In light of our 
new findings, such worsened performance could be related to the progressive posterior 
parietal and temporal thinning observed in PD.   
At last but not least, we would like to highlight as important limitation the high attrition 
rate, especially concerning pattern 1 patients. For this reason, we stated in the methods 






In summary, patients from pattern 1 were mainly lost to follow-up due to functional 
impairment in IALD.  Patients from pattern 2 showed modest progressive temporal and 
parietal cortical thinning and probably better evolution. Finally, pattern 3 patients were 
non-atrophic at baseline but progressed showing temporo-parietal cortical thinning. In 
conclusion, cortical thinning in PD subtypes follows different progression over time. 
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Figure 1 Neuropsychological and cortical thinning effect times. A) Neuropsychological 
performance of pattern 2 and 3 PD patients and controls at both times. Time 1 in blue and 
time 2 in orange. Data are presented as adjusted z-scores. z-scores were calculated based 
on the control group’s means and standard deviations at time 1. Expected z-scores 
adjusted for age, sex, and education for each test and each subject were calculated based 
on a multiple regression analysis performed in the HC group. Lower z-scores indicate 
worse performance.  Abbreviations: BNT = Boston Naming Test; JLO = Judgment of Line 
Orientation Test; RAVLT = Rey’s Auditory Verbal Learning Test; SDMT = Symbol Digits 
Modalities Test; TMT = Trail Making Test; VFD = Visual Form Discrimination Test. B) 
symmetrized percent of change of cortical thickness. Color maps indicate significant time 
effect in each group. Results were corrected by Monte Carlo simulation.  
 
Figure 2 Symmetrized percent of change of cortical thickness from the group per 







Table 1 Demographic and clinical characteristics of the sample at both times  
  











Age, y, median (IQ range)  
Time 1  76.0 (18.0) 57.5 (13.0) 63.0 (10.0) 66.0 (13.0) 13.740/.003 




8.0 (6.0) 17.5 (8.0) 10.5 (6.0) 10.0 (8.0) 16.492/.001 
Sex, male, n 
(%)  
6 (86.7) 13 (81.3) 12 (54.5) 11 (50.0) 6.081/.108 
Disease duration, y, median (IQ range) 
Time 1  4.0 (7.0) 6.0 (8.3) 6.0 (9.0) NA 1.564/.457 
Time 2  7.0 (7.0) 9.0 (7.0) 9.0 (7.0) NA 0.278/.870 
Age of onset, 
y, median (IQ 
range) 
67.0 (19.0) 47.5 (14.6) 54.5 (12.7) NA 10.583/.005 
Hoehn &Yahr stage, n 1/1.5/2/2.5/3/4  
Time 1  2/0/5/0/0/0 5/1/7/2/1/0 11/0/8/1/2/0 NA 6.466/.595 
Time 2  0/0/2/0/4/1 2/0/6/0/8/0 4/0/11/0/7/0 NA 8.629/.196 
Instrumental Activities of Daily Living Scales, median (IQ range)  
Lawton and 
Brody Scale  
3.5 (2.0) 7.0 (3.0) 8.0 (2.0) 8.0 (2.0) 17.096/.001 
Schwab and 
England 
Scale, %  
70.0 (20.0) 85.0 (30.0) 90.0 (20.0) 100.0 (0.0) 33.105/<.001 




MCI1  3 (42.8) 7 (43.8) 11 (50.0) 1 (4.5) 
Dementia1  2 (28.6) 0 0 0 
IQ range, interquartile range; MCI, mild cognitive impairment; NA, not applicable.  
P-values are from Kruskal-Wallis test followed by Mann-Whitney pairwise test and 
Bonferroni correction for continuous variables and chi-squared test for categorical variables.   
1 Proportions of noMCI, MCI and dementia at time 2.  
2 Chi squared test between all groups was 80.136; P<.001. Chi squared test between PD 
groups was 11.734; P=.019.  
Age showed significant differences between pattern 2 and HC (P=.013 at time 1; P=.015 at time 
2) and pattern 1 (P=.009 at time 1; P=.007 at time 2). Years of education showed significant 
differences between pattern 2 and HC (P=.016), pattern 1 (P =.003) and pattern 3 (P =.011). Age 
of onset showed significant differences between pattern 1 and pattern 2 (P =.005). At time 2, 





pattern 3 (P=.003); Schwab and England Scale showed significant differences between pattern 
1 and HC (P<.001), and pattern 2 (P<.001), and pattern 3 (P=.003).  
Table 2 Clinical measures of the sample at both times  
  









Mini Mental State Examination, mean (SD)  
Time 1  28.3 (2.0) 29.6 (0.6) 29.3 (0.9) 29.8 (0.4) 
Time 2  25.7 (4.5) 29.1 (1.0) 29.1 (1.0) 29.3 (0.8) 
UPDRS part III, mean (SD)  
Time 1  13.7 (7.0) 13.8 (11.3) 12.5 (9.5) NA 
Time 2  23.9 (15.4) 19.1 (9.5) 14.5 (7.8) NA 
LEDD, mg, mean (SD)  
Time 1  552.9 (386.0) 849.4 (557.9) 603.3 (445.5) NA 
Time 2  924.3 (484.5) 672.8 (326.6) 694.6 (462.1) NA 
Beck Depression Inventory II, mean (SD)  
Time 1  13.9 (5.2) 6.4 (6.1) 8.9 (4.7) 6.6 (5.5) 
Time 2  19.7 (9.4) 6.6 (5.3) 8.3 (4.8) 5.1 (4.6) 
Starkstein’s Apathy Scale, mean (SD)  
Time 1  19.1 (7.5) 11.1 (7.3) 10.7 (5.7) 8.6 (5.8) 
Time 2  23.0 (7.0) 10.6 (8.2) 11.3 (5.9) 9.1 (5.5) 
Cummings’ Neuropsychiatric Inventory, mean (SD)  
Time 1  9.1 (13.7) 5.8 (10.5) 5.4 (6.4) 1.8 (3.5) 
Time 2  20.6 (16.4) 9.8 (9.8) 6.2 (6.0) 2.2 (2.5) 
LEDD, L-dopa equivalent daily dose; SD, Standard deviation; UPDRS part III, Unified 
Parkinson’s Disease Rating Scale motor section.  
Pattern 1 patients were not included into the permutation testing general linear model. All 
reported significant effects were corrected by Bonferroni. 
There were significant time effects in MMSE in pattern 2 (t=1.804; =.054) and in controls 
(t=1.923; P=.035). There was a significant interaction time x group in LEDD medication 
between pattern 2 and pattern 3 (t=1.825; P=.047). Cummings’ Neuropsychiatric Inventory 
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Supplementary Figure 1 Flowchart of participants who participated at both times 
and those lost to time 2 
Abbreviations: DBS = deep brain stimulation; IADL = instrumental activities of daily 
living; MRI = magnetic resonance imaging; P1 = Pattern 1; P2 = Pattern 2; P3 = Pattern 





Supplementary Table 1 Neuropsychological performance at time 1 and 2 of PD 
subtypes and healthy controls  
 Parkinson's disease subtypes healthy  
controls 





Pattern 3 (n=22) 
Visual Form Discrimination, mean (SD) 
Time 1 -0.9 (1.2)  -0.5 (0.7)  -0.6 (1.3)  0.1 (0.8)  
Time 2 -1.2 (1.6)  -0.2 (1.0)  -0.2 (0.9)  0.1 (0.9)  
Judgement of Line Orientation, mean (SD) 
Time 1 -0.6 (1.0)  -0.6 (1.3)  -0.2 (1.0)  0.1 (0.7)  
Time 2 -0.8 (1.5)  -0.1 (0.7)  -0.0 (0.9)  0.4 (0.6)  
Phonetic fluency, mean (SD) 
Time 1 -0.1 (0.9)  0.1 (1.1)  -0.1 (1.2)  -0.0 (1.0)  
Time 2 -1.1 (1.0)  0.1 (1.1)  -0.3 (0.8)  -0.1 (1.0)  
Semantic fluency, mean (SD) 
Time 1 -1.0 (0.7)  0.0 (1.1)  -0.4 (1.1)  -0.2 (0.6)  
Time 2 -1.9 (1.3)  -0.4 (0.7)  -0.9 (1.5)  -0.4 (0.7)  
RAVLT total, mean (SD) 
Time 1 -0.5 (1.2)  -0.7 (1.4)  -0.3 (1.3)  -0.0 (0.8)  
Time 2 -0.9 (2.2)  -0.5 (1.4)  -0.1 (1.2)  0.6 (0.9)  
RAVLT recall, mean (SD) 
Time 1 -0.6 (1.0)  -0.7 (1.4)  -0.5 (1.1)  0.0 (0.9)  
Time 2 -1.1 (0.8)  -0.8 (1.5)  -0.2 (1.6)  0.6 (1.0)  
RAVLT recognition, mean (SD) 
Time 1 0.5 (1.7)  -0.7 (1.9)  -0.0 (1.3) -0.3 (0.9) 
Time 2 0.3 (1.1)  -0.5 (1.4)  -0.1 (1.3) 0.6 (0.5) 
Digits forward, mean (SD) 
Time 1 -0.2 (0.6)  -0.6 (0.9)  -0.0 (1.0)  -0.1 (0.8)  
Time 2 -0.3 (0.6)  -0.7 (1.0)  -0.3 (0.9)  -0.3 (0.9)  
Digits backward, mean (SD) 
Time 1 0.1 (0.7)  -0.4 (0.7)  0.2 (1.0)  0.0 (0.9)  
Time 2 -0.1 (0.6)  -0.1 (1.1)  -0.1 (0.8)  0.2 (0.7)  
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Stroop Word test, mean (SD) 
Time 1 -1.0 (1.6)  -0.9 (1.5)  -0.8 (1.5)  -0.0 (0.9)  
Time 2 -1.8 (1.7)  -1.1 (0.9)  -0.8 (0.9)  -0.1 (0.7)  
Stroop Color test, mean (SD) 
Time 1 -0.6 (0.8)  -0.3 (0.9)  -0.0 (0.8)  0.1 (1.0)  
Time 2 -1.1 (1.2)  -0.8 (0.9)  -0.4 (0.8)  0.2 (0.7)  
Stroop Word-Color test, mean (SD) 
Time 1 -0.3 (0.7)  0.1 (0.9)  0.1 (0.7)  0.2 (0.8)  
Time 2 -0.6 (1.1)  -0.3 (0.8)  -0.3 (0.7)  0.1 (0.8)  
Symbol Digits Modalities test, mean (SD) 
Time 1 -1.0 (1.3)  -0.4 (1.1)  -0.4 (0.9)  -0.2 (0.6)  
Time 2 -1.4 (1.2)  -0.8 (1.1)  -0.6 (0.9)  0.0 (0.7)  
Trail Making Test Part A, mean (SD) 
Time 1 -2.0 (4.8)  -0.4 (1.1)  -0.5 (1.8)  -0.0 (0.9)  
Time 2 -5.7 (8.0)  -1.2 (2.2)  -1.3 (2.0)  0.1 (0.7)  
Trail Making Test Part B, mean (SD) 
Time 1 NA -0.4 (0.7)  -0.9 (2.4)  0.1 (0.7)  
Time 2 NA -1.8 (3.4)  -2.6 (4.9)  0.0 (1.1)  
Trail Making Test A minus B, mean (SD) 
Time 1 NA -0.3 (0.6) -0.9 (2.3) 0.2 (0.6) 
Time 2 NA -1.8 (3.1) -2.1 (4.1) -0.2 (0.9) 
Boston Naming Test, mean (SD) 
Time 1 -0.1 (0.7) -0.2 (0.8) 0.0 (0.9) 0.1 (0.8) 
Time 2 0.1 (1.0) -0.5 (0.8) 0.3 (0.7) 0.4 (0.6) 
NA, not applicable; RAVLT, Rey’s Auditory Verbal Learning Test; SD, standard deviation. 
Data are z-scores adjusted by age, education and sex. 
Permutation tests were calculated with 10,000 iterations. Pattern 1 patients were not 
included in the permutation testing due to small sample size. 
There was a significant time effect in pattern 2 concerning semantic fluency (t=2.041; 
P=.010), Stroop Color (t=2.284; P=.049), Stroop Word-Color (t=2.985; P=.009), Symbol 
Digits Modalities (t=2.231; P=.048), Trail Making Test Part B (t=2.188; P=.029) and Part 
A minus B (t=2.545; P=0.001). There was a trend between pattern 2 and controls in 
Stroop Color (t=2.182; P=.058) and there was significant group effect in Symbol Digits 
Modalities (t=2.639; P=.018). 
There was a significant time effect in pattern 3 concerning semantic fluency (t=2.592; 
P=.029), Stroop Word-Color (t=2.970; P=.001), Symbol Digits Modalities (t=1.728; 
P=.006), Trail Making Test Part A (t=3.390; P=.004), Part B (t=2.775; P=.005) and A minus 
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B (t=2.192; P=.059). There were significant differences between pattern 3 and HC in 
Symbol Digits Modalities (t=2.218; P=.008), Trail Making Test Part A (t=2.615; P=.032) 
and Part B (t=1.826; P=.030).  




Supplementary Table 2 Proportion of mild cognitive impairment or PD dementia 
converters within groups  
 Parkinson's disease subtypes healthy  
controls  
(n=22)  






converters, n (%)  4 (57.1) 4 (25.0) 6 (27.3)  1 (4.5) 
no-converters, n 
(%)   
3 (42.9) 12 (75.0) 16 (72.7)  21 (95.5)  
Chi squared test between all groups was 9.262; P=.026. Chi squared test between PD 





Supplementary Table 3 Cortical thickness information of longitudinal analysis 








Left superior temporal 2,106.4 -4.561 <.001 -45 -11 -15 
Left lingual 2,147.1 -4.207 <.001 -19 -49 -2 
Left inferior parietal 5,899.5 -3.948 <.001 -42 -72 32 
Left superior parietal 2,472.0 -3.198 <.001 -29 -45 55 
Right supramarginal 18,882.9 -5.265 <.001 59 -42 24 
Right pars orbitalis 973.5 2.513 0.040 41 43 -6 
Pattern 2  
Left inferior parietal 1,481.1 -3.537 .003 -33 -78 38 
Left fusiform 2,512.0 -3.478 <.001 -37 -40 -23 
Right middle temporal 4,387.0 -3.801 <.001 57 -44 -10 
Pattern 3  
Left precuneus 13,671.2 -5.683 <.001 -10 -53 24 
Left superior temporal 7,047.5 -4.885 <.001 -51 6 -21 
Left lingual 2,832.7 -4.345 <.001 -29 -56 -7 
Left caudal middle 
frontal 
2,128.7 -2.830 <.001 -39 5 46 
Right lingual 33,004.4 -5.612 <.001 20 -51 -4 
Group per time effects 
healthy controls vs Pattern 3 
Left pars opercularis 1,343.8 2.548 .006 -49 12 2 
Left precentral 1,232.1 2.395 .012 -34 -15 43 
Pattern 3 vs Pattern 2  
Right lateral occipital 2,492.9 4.440 <.001 28 -94 8 
1MNI305 space.  
Results were obtained using Monte Carlo simulation with 10.000 iterations applied to 
cortical thickness maps to provide clusterwise correction for multiple comparisons (1.3). 






Supplementary Table 4 Global atrophy measures   
 Parkinson's disease subtypes healthy 
controls  
(n=22) 






Mean thickness, mm, mean (SD)  
Time 1    2.4 (0.1)  2.4 (0.1)   2.5 (0.1)   2.5 (0.7)   
Time 2    2.4 (0.2)   2.4 (0.1)   2.4 (0.2)   2.5 (0.1)  
Lateral ventricles, mm3, mean (SD)   
Time 1    13,794.3 
(7,381.0)  
10,731.0 
(4,664.2)   
11,273.2 
(6,970.8)   
 9,359.2 
(4,167.1)  








Total gray matter, mm3, mean (SD)   







(31,781.1)   








Cortical gray matter, mm3, mean (SD)   
















Subcortical gray matter, mm3, mean (SD)   
















* one PD patient was excluded due to motion artifacts. 
SD, standard deviation.  
Permutation tests were calculated with 10,000 iterations.  
Pattern 1 patients were not included in the permutation testing due to small sample size. 
There were significant time effects in total gray matter (pattern 2: t=3.226; P=.018; pattern 
3: t=6.412; P<.001; controls: t=3.228; P=.005), in cortical gray matter (pattern 3: t=4.969; 
P<.001; controls: t=2.476; P=.032) and in subcortical gray matter (pattern 2: t=2.674; 
P=.053). There was an interaction group x time between pattern 2 and pattern 3 patients 
in lateral ventricles (t=-2.827; P=.008), total gray matter (t=3.124; P=.003) and cortical 




Supplementary Table 5 Demographical and clinical characteristics of completers 
and non-completers  
  Parkinson’s disease subtypes  healthy 
controls  
   Pattern1 Pattern2  Pattern3 
n non-
completers  
23/30 13/29 7/29 9/31 
Age, y, median (IQ range)  
completers  76.0 (18.0) 57.5 (13.0) 63.0 (10.0) 66.0 (13.0) 
non-completers 73.0 (13.0) 64.0 (19.0) 66.0 (11.0) 65.0 (18.0) 
Education, y, median (IQ range)  
completers  8.0 (6.0) 17.5 (8.0) 10.5 (6.0) 10.0 (8.0) 
non-completers  7.0 (5.0) 9.0 (8.0) 10.0 (5.0) 9.0 (8.0) 
Sex, male, n (%)  
completers  6 (86.7) 13 (81.3) 12 (54.5) 11 (50.0) 
non-completers  9 (39.1) 7 (53.8) 4 (57.1) 5 (55.6) 
Mini Mental State Examination, median (IQ range)  
completers  29.0 (4.0) 30.0 (1.0) 30.0 (1.0) 30.0 (0.0) 
non-completers  29.0 (2.0) 29.0 (1.0) 30.0 (1.0) 29.0 (1.0) 
Disease duration, y, median (IQ range)  
completers  4.0 (7.0) 6.0 (8.3) 6.0 (8.5) NA 
non-completers  9.0 (12.0) 8.0 (9.0) 5.0 (11.0) NA 
Age of onset, y, median (IQ range)  
completers  67.0 (19.0) 47.5 (14.6) 54.5 (12.8) NA 
non-completers  63.0 (22.0) 55.0 (12.5) 61.0 (21.0) NA 
UPDRS part III, median (IQ range)  
completers  13.0 (12.0) 12.0 (20.0) 11.5 (14) NA 
non-completers 17.0 (13.0) 12.0 (16.0) 15.0 (3.0) NA 
Hoehn&Yahr stage, n 1/1.5/2/2.5/3  
completers  2/0/5/0/0 5/1/7/2/1 11/0/8/1/2 NA 
non-completers  0/3/11/4/5 4/1/6/1/1 0/0/6/1/1 NA 
LEDD, mg, median (IQ range)  
completers  400.0 (450.0) 
800.0 
(1150.0) 
485.0 (639.0) NA 
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Beck Depression Inventory II, median (IQ range)  
completers  14.0 (6.0) 5.0 (7.0) 8.0 (5.0) 6.0 (9.0) 
non-completers 15.5 (9.0) 11.5 (11.0) 7.0 (12.0) 2.0 (8.0) 
Starkstein’s Apathy Scale, median (IQ range)  
completers 17.0 (12.0) 8.0(11.0) 10.0 (10.0) 10.0 (11.0) 
non-completers  14.0 (14.0) 13.5 (13.0) 11.0 (9.0) 9.0 (4.0) 
Cummings’ Neuropsychiatric Inventory, median (IQ range)  
completers 2.0 (26.0) 2.5 (6.0) 4.0 (9.0) 0.0 (3.0) 
non-completers  3.5 (9.0) 1.0 (5.0) 7.0 (9.0) 0.0 (0.0) 
MCI at time 1, n (%)  
completers  3 (42.9) 6 (37.5) 7 (31.8) NA 
non-completers 17 (73.9) 8 (61.5) 4 (57.1) NA 
IQ range, Interquartil range; LEDD, L dopa equivalent daily dose; MCI, mild cognitive 
impairment;NA, not applicable; UPDRS part III, Unified Parkinson’s Disease Rating Scale 
motor section.  
Mann-Whitney pairwise test for continuous variables and chi-squared test for categorical 
variables were calculated.  
There were significant differences between completers and non-completers of pattern 1 
in sex (chi=4.658; P=.031) and Hoehn & Yahr stage (chi=10.784; P=.029). There were 
significant differences between completers and non-completers of pattern 2 in education 
(U=40.500; P=.004), Mini Mental State Examination (U=58.500; P=.045) and Beck 
Depression Inventory-II (U=108.000; P=.026). There were significant differences 































43.5 (50.3) 6.0 (12.3) 12.0 (6.5) 15.791/<.001 
GBS-I, intellectual impairment; GBS-E, emotional impairment; GBS-ADL, impairment of 
Activity Daily Living performance; GBS-S, symptoms common in dementia. 
Two familiars refused to complete the interview and 14 were impossible to contact for 
telephonic interview. From these 14, two patients were still working. 
P-values are from Kruskal-Wallis test followed by Mann-Whitney pairwise test and 
Bonferroni correction. 
There were significant differences between pattern 1 and pattern 2 in GBS-I (P=.004), 
GBS-ADL (P=.007), GBS-S (P=.017) and GBS total score (P=.005). There were 
significant differences between pattern 1 and pattern 3 in GBS-I (P=.007), GBS-E 
(P=.021), GBS-ADL (P=.004), GBS-S (P=.016) and GBS total score (P=.004). 
 
 
 
 
 
